BIOLARGO INC - BLGO STOCK NEWS

BioLargo's subsidiary, Clyra Medical Technologies, has selected Keystone Industries to support the manufacturing of its medical products, specifically the Bioclynse surgical wound irrigation solution. Bioclynse is FDA 510(k) cleared, non-cytotoxic, and effective against biofilms, presenting significant benefits for patient outcomes in surgeries and dentistry. Keystone, a global manufacturer with over a century of experience, has committed significant investment in infrastructure to scale up production. Both companies have emphasized the importance of this collaboration for the successful market launch of Bioclynse.

BioLargo (OTCQX:BLGO) has successfully manufactured its first Cellinity™ 'Liquid Sodium' prototype battery cells. The Cellinity battery platform aims to provide safer, long-lasting, and environmentally friendly energy storage alternatives to lithium-ion batteries. These prototype cells will undergo testing and validation to confirm performance claims. Cellinity batteries boast several advantages: safety (no fire or explosion risk), longevity (no performance drop after thousands of cycles), high energy density, and the use of North American-sourced materials without rare-earth elements. Future plans include manufacturing full-scale prototype modules and exploring financing options, focusing on community-based partnerships.

BioLargo (OTCQX:BLGO) announced that its engineering subsidiary has secured a multi-year contract to provide air quality services to three U.S. Air Force bases in New Mexico. The contract, potentially generating $650,000 annually, spans up to five years and represents the company's largest Air Force contract to date. This new agreement adds to BioLargo's ongoing environmental support at six other Air Force bases. The contract ensures regular monthly flat fee revenue over its duration, with annual renewal options. Bhate Environmental Associates is the prime contractor under the Fence-to-Fence (F2F) support contract. BioLargo's President, Randall Moore, emphasized the importance of such long-term contracts for steady income and the commercialization of their cleantech innovations.

BioLargo (OTCQX:BLGO) reported positive operating cash flow of $481,000 and record quarterly revenues of $4,760,000 for Q1 2024, reflecting a 9% increase over Q4 2023 and a 28% increase over Q1 2023. The company's net stockholder's equity rose from $4.2 million to $5.1 million. Despite a net loss of $775,000, this represents a 32% decrease compared to the prior quarter. Significant business developments include launching a water equipment subsidiary and securing key industry leaders on its board. The U.S. EPA's new PFAS regulations could benefit BioLargo's technology. The company continues to invest in scaling up its Bioclynse product line.

BioLargo, Inc. (BLGO) will host an investor webcast and conference call on May 14, 2024, to discuss financial results for Q1 2024, recent milestones, and conduct a Q&A session. The event will be open to the public, covering sustainable technologies for environmental challenges.

BioLargo (BLGO) applauds EPA's decision to regulate PFAS chemicals under the Superfund law, favoring low-waste systems like BioLargo's AEC. The Aqueous Electrostatic Concentrator generates significantly less waste than carbon filtration, reducing operational costs. EPA's designation of PFAS as 'hazardous substances' under CERCLA will expedite cleanups and ensure polluters pay for the costs. BioLargo sees a competitive advantage over sorbent technologies with these new regulations, offering clients waste handling to full destruction at their facility. The EPA's commitment of $9 billion in funding to address PFAS contamination is also welcomed by BioLargo's President and CEO.

BioLargo's Aqueous Electrostatic Concentrator surpasses US EPA drinking water standards for PFAS removal, generating less waste and reducing costs for customers. The technology offers advisory services, analytical testing, and education on PFAS science and regulations. The new regulations set national limits for PFAS in public drinking water at nearly undetectable levels, costing approximately $1.5 billion annually for compliance.

BioLargo, Inc. (BLGO) reports a significant 108% increase in annual revenues year-over-year compared to 2022. The company focuses on sustainable technologies for environmental challenges. The CEO highlights rising odor control product sales and the potential of PFAS solutions for future growth. BioLargo aims to leverage intellectual property and partnerships for sales expansion while maintaining financial stability.

BioLargo, Inc. (BLGO) to host an investor webcast and conference call to discuss financial results and recent milestones for the year ending December 31, 2023.